User menu

Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group

Bibliographic reference Callens, C ; Chevret, S ; Cayuela, JM ; Cassinat, B. ; Raffoux, E. ; et. al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. In: Leukemia, Vol. 19, no. 7, p. 1153-1160 (2005)
Permanent URL
  1. D. Kottaridis Panagiotis, Gale Rosemary E., Linch David C., Flt3 mutations and leukaemia, 10.1046/j.1365-2141.2003.04500.x
  2. Radich JP, Blood, 76, 801 (1990)
  3. Kiyoi H, Blood, 93, 3074 (1999)
  4. Stirewalt D. L., FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia, 10.1182/blood.v97.11.3589
  5. Yokota S, Leukemia, 11, 1605 (1997)
  6. Kiyoi H, Leukemia, 11, 1447 (1997)
  7. Yamamoto Y., Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies, 10.1182/blood.v97.8.2434
  8. Frohling S., Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm, 10.1182/blood-2002-05-1440
  9. Liang DC, Leukemia, 17, 883 (2003)
  10. Sheikhha MH, Hematol J, 4, 41 (2003)
  11. Andersson Anna, Johansson Bertil, Lassen Carin, Mitelman Felix, Billstrom Rolf, Fioretos Thoas, Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients, 10.1111/j.1600-0609.2004.00225.x
  12. Schnittger S., Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease, 10.1182/blood.v100.1.59
  13. Thiede C., Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis, 10.1182/blood.v99.12.4326
  14. CIOLLI S, VANNUCCHI AM, LEONI F, NOZZOLI C, LONGO G, SALATI A, PANCRAZZI A, BIANCHI L, GIGLI F, BOSI A, Internal Tandem Duplications ofFlt3Gene (Flt3/ITD) Predicts a Poor Post-Remission Outcome in Adult Patients with Acute Non-Promyelocytic Leukemia, 10.1080/1042819031000151851
  15. Beran Miloslav, Luthra Rajyalakshmi, Kantarjian Hagop, Estey Elihu, FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype, 10.1016/j.leukres.2003.09.016
  16. Boissel N, Leukemia, 16, 1699 (2002)
  17. Liang Der-Cherng, Shih Lee-Yung, Hung Iou-Jih, Yang Chao-Ping, Chen Shu-Huey, Jaing Tang-Her, Liu Hsi-Che, Chang Wan-Hui, Clinical relevance of internal tandem duplication of theFLT3 gene in childhood acute myeloid leukemia, 10.1002/cncr.10598
  18. Moreno I, Haematologica, 88, 19 (2003)
  19. Steudel Christine, Wermke Martin, Schaich Markus, Schäkel Ulrike, Illmer Thomas, Ehninger Gerhard, Thiede Christian, Comparative analysis ofMLLpartial tandem duplication andFLT3internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia : MLLPTD andFLT3ITD Mutations in AML, 10.1002/gcc.10219
  20. Libura M., FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress, 10.1182/blood-2003-01-0162
  21. Valk PJ, Haematologica, 89, 106 (2004)
  22. Iwai T, Leukemia, 13, 38 (1999)
  23. Rombouts WJ, Leukemia, 14, 675 (2000)
  24. Meshinchi S., Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia, 10.1182/blood.v97.1.89
  25. Kottaridis P. D., The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials, 10.1182/blood.v98.6.1752
  26. Whitman SP, Cancer Res, 61, 7233 (2001)
  27. Zwaan C. M., FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance, 10.1182/blood-2002-12-3627
  28. Abu-Duhier F. M., Goodeve A. C., Wilson G. A., Gari M. A., Peake I. R., Rees D. C., Vandenberghe E. A., Winship P. R., Reilly J. T., FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group, 10.1046/j.1365-2141.2000.02317.x
  29. Neubauer A, Blood, 83, 1603 (1994)
  30. Coghlan DW, Leukemia, 8, 1682 (1994)
  31. Fenaux P, Blood, 94, 1192 (1999)
  32. Fenaux P, Blood, 82, 3241 (1993)
  33. Gabert J, Leukemia, 17, 2318 (2003)
  34. Abu-Duhier F. M., Goodeve A. C., Wilson G. A., Care R. S., Peake I. R., Reilly J. T., Genomic structure of human FLT3: implications for mutational analysis, 10.1046/j.1365-2141.2001.02821.x
  35. Kaplan E, J Am Stat Assoc, 53, 457 (1958)
  36. Peto R, J Roy Stat Soc, 135, 185 (1972)
  37. Gray RJ, Ann Stat, 16, 1141 (1998)
  38. Fine JP, JASA, 94, 496 (1999)
  39. Sanz MA, Blood, 96, 1247 (2000)
  40. Kainz B, Hematol J, 3, 283 (2002)
  41. Noguera NI, Leukemia, 16, 2185 (2002)
  42. Arrigoni Paolo, Beretta Chiara, Silvestri Daniela, Rossi Vincenzo, Rizzari Carmelo, Valsecchi Maria Grazia, Cazzaniga Giovanni, Biondi Andrea, FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia, 10.1046/j.1365-2141.2003.04032.x
  43. Shih Lee-Yung, Kuo Ming-Chung, Liang Der-Cherng, Huang Chein-Fuang, Lin Tung-Liang, Wu Jin-Hou, Wang Po-Nan, Dunn Po, Lai Chang-Liang, Internal tandem duplication and Asp835 mutations of theFMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia : Correlation with molecular subtypes ofPML/RAR? and clinical features, 10.1002/cncr.11636
  44. Longo L, Leuk Lymphoma, 11, 405 (1993)
  45. Kottaridis P. D., Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors, 10.1182/blood-2002-02-0420
  46. Tiesmeier Jens, Müller-Tidow Carsten, Westermann Annette, Czwalinna Andreas, Hoffmann Mandy, Krauter Jürgen, Heil Gerhard, Ganser Arnold, Serve Hubert, Verbeek Walter, Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy, 10.1016/j.leukres.2004.02.009